Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease therapies, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's CEO, Shalabh Gupta, M.D., will engage in a fireside chat on October 17, 2024, at 10:00 a.m. ET.
Interested parties can access the live and archived webcast through the Unicycive website under the Investors section, specifically in the Events and Presentations area. The webcast archive will remain available for three months following the event.
This participation provides an opportunity for investors and stakeholders to gain insights into Unicycive's developments and strategies in the field of kidney disease treatments.
Unicycive Therapeutics (Nasdaq: UNCY), una compagnia biotech in fase clinica focalizzata sulle terapie per le malattie renali, ha annunciato la sua partecipazione al 2024 Maxim Healthcare Virtual Summit. Il CEO dell'azienda, Shalabh Gupta, M.D., parteciperà a una chat informale il 17 ottobre 2024, alle 10:00 a.m. ET.
Le parti interessate possono accedere al webcast live e archiviato attraverso il sito web di Unicycive nella sezione Investitori, specificamente nell'area Eventi e Presentazioni. L'archivio del webcast rimarrà disponibile per tre mesi dopo l'evento.
Questa partecipazione offre un'opportunità agli investitori e ai soggetti interessati di acquisire informazioni sui progressi e le strategie di Unicycive nel campo dei trattamenti per le malattie renali.
Unicycive Therapeutics (Nasdaq: UNCY), una compañía de biotecnología en etapa clínica centrada en terapias para enfermedades renales, ha anunciado su participación en el 2024 Maxim Healthcare Virtual Summit. El CEO de la empresa, Shalabh Gupta, M.D., participará en una charla informal el 17 de octubre de 2024, a las 10:00 a.m. ET.
Las partes interesadas pueden acceder a la transmisión en vivo y archivada a través del sitio web de Unicycive en la sección de Inversores, específicamente en el área de Eventos y Presentaciones. El archivo de la transmisión estará disponible durante tres meses después del evento.
Esta participación brinda una oportunidad para que los inversores y las partes interesadas obtengan información sobre los avances y estrategias de Unicycive en el campo de los tratamientos para enfermedades renales.
Unicycive Therapeutics (Nasdaq: UNCY)는 신장 질환 치료에 집중하는 임상 단계의 생명공학 회사로, 2024 Maxim Healthcare Virtual Summit에 참여한다고 발표했습니다. 회사의 CEO인 Shalabh Gupta, M.D.는 2024년 10월 17일 오전 10시 ET에 화상 대화에 참석할 예정입니다.
관심 있는 당사자는 Unicycive 웹사이트의 투자자 섹션, 특히 이벤트 및 발표 분야를 통해 라이브 및 아카이브 웹캐스트에 접근할 수 있습니다. 웹캐스트 아카이브는 이벤트 후 3개월 동안 제공됩니다.
이번 참여는 투자자와 이해관계자들이 Unicycive의 신장 질환 치료에 대한 개발 및 전략에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
Unicycive Therapeutics (Nasdaq: UNCY), une société de biotechnologie en phase clinique axée sur les thérapies des maladies rénales, a annoncé sa participation au 2024 Maxim Healthcare Virtual Summit. Le PDG de l'entreprise, Shalabh Gupta, M.D., participera à une conversation informelle le 17 octobre 2024 à 10h00 ET.
Les parties intéressées peuvent accéder à la diffusion en direct et archivée via le site Web d'Unicycive dans la section Investisseurs, plus précisément dans la zone Événements et Présentations. L'archive de la diffusion restera disponible pendant trois mois après l'événement.
Cette participation offre aux investisseurs et aux parties intéressées l'occasion d'obtenir des informations sur les développements et les stratégies d'Unicycive dans le domaine des traitements des maladies rénales.
Unicycive Therapeutics (Nasdaq: UNCY), ein Biotechnologieunternehmen in der klinischen Phase, das sich auf Therapien für Nierenerkrankungen konzentriert, hat seine Teilnahme am 2024 Maxim Healthcare Virtual Summit bekannt gegeben. Der CEO des Unternehmens, Shalabh Gupta, M.D., wird am 17. Oktober 2024 um 10:00 Uhr ET an einem Fireside-Chat teilnehmen.
Interessierte Parteien können über die Unicycive-Website im Bereich Investoren, insbesondere im Bereich Veranstaltungen und Präsentationen, auf die Live- und aufgezeichnete Übertragung zugreifen. Das Archiv der Übertragung bleibt drei Monate nach der Veranstaltung verfügbar.
Diese Teilnahme bietet Investoren und Interessierten die Möglichkeit, Einblicke in die Entwicklungen und Strategien von Unicycive im Bereich der Behandlungen von Nierenerkrankungen zu erhalten.
- None.
- None.
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Investor Contact:
ir@unicycive.com
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
FAQ
When is Unicycive Therapeutics (UNCY) participating in the 2024 Maxim Healthcare Virtual Summit?
Who will represent Unicycive Therapeutics (UNCY) at the 2024 Maxim Healthcare Virtual Summit?
How can investors access the webcast of Unicycive Therapeutics' (UNCY) fireside chat?
How long will the archived webcast of Unicycive Therapeutics' (UNCY) fireside chat be available?
What is the main focus of Unicycive Therapeutics (UNCY) as a biotechnology company?
